Satellos to Present Phase 1a/b Data for SAT-3247 at 2026 MDA Conference
Event summary
- Satellos will present two oral and three poster presentations at the 2026 MDA Clinical & Scientific Conference (March 8-11).
- Oral presentations include Phase 1a/b data for SAT-3247 in healthy volunteers and DMD patients, plus preclinical FSHD mouse model data.
- Poster sessions cover Phase 1a/b trial results, Phase 2 TRAILHEAD study design, and regenerative potential in DMD patients aged 7-11.
- SAT-3247 targets AAK1 protein to restore muscle stem cell signaling disrupted in DMD.
The big picture
Satellos' presentations at the 2026 MDA Conference highlight its progress in developing SAT-3247, a novel oral therapy targeting muscle regeneration in DMD and potentially other degenerative muscle conditions. The focus on preclinical and Phase 1a/b data suggests the company is advancing toward critical efficacy and safety milestones. The broader industry trend of targeting muscle repair mechanisms positions Satellos in a competitive space with other biotechs developing disease-modifying treatments for rare neuromuscular disorders.
What we're watching
- Clinical Efficacy
- Whether SAT-3247 demonstrates meaningful muscle force improvement in FSHD mouse model data.
- Regulatory Pathway
- The pace at which Satellos advances SAT-3247 toward Phase 2 trials in DMD patients.
- Market Opportunity
- How Satellos positions SAT-3247 as a potential treatment for multiple degenerative muscle diseases.
Related topics